Skip to main content

Table 2 Summary of the subgroup analyses in observational studies

From: The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis

Subgroups Number of studies Sample size OR 95% CI P I2
Definition of antiplatelet therapy
 Aspirin only 3 5379 0.67 (0.52–0.86) 0.829 0.0%
 Aspirin in combination 4 1848 0.67 (0.44–1.02) 0.003 78.8%
Time of antiplatelet therapy
 Before hospitalization 3 5379 0.67 (0.52–0.86) 0.829 0.0%
 Before and/or after hospitalization 4 1848 0.67 (0.44–1.02) 0.003 78.8%
Risk factors for ARDS
 Sepsis
  Yes 5 5703 0.69 (0.50–0.95) 0.004 74.3%
  No 2 1524 0.64 (0.46–0.90) 0.603 0.0%
 Shock
  Yes 3 4834 0.74 (0.52–0.88) 0.062 63.9%
  No 4 2393 0.61 (0.48–0.77) 0.364 5.8%
 Pneumonia
  Yes 3 4834 0.74 (0.52–0.88) 0.062 63.9%
  No 4 2393 0.61 (0.48–0.77) 0.364 5.8%
 Aspiration
  Yes 3 4834 0.74 (0.52–0.88) 0.062 63.9%
  No 4 2393 0.61 (0.48–0.77) 0.364 5.8%
 Trauma       
  Yes 3 4834 0.74 (0.52–0.88) 0.062 63.9%
  No 4 2393 0.61 (0.48–0.77) 0.364 5.8%
 High-risk surgery
  Yes 3 1411 0.90 (0.85–0.95) 0.609 0.0%
  No 4 5816 0.59 (0.48–0.73) 0.352 8.2%
 Pancreatitis
  Yes 3 4834 0.74 (0.52–0.88) 0.062 63.9%
  No 4 2393 0.61 (0.48–0.77) 0.364 5.8%
 Massive transfusion
  Yes 1 218 0.91 (0.49–1.69)
  No 5 7009 0.65 (0.48–0.87) 0.002 73.6%
Definition of ARDS
 Berlin definition 1 375 0.46 (0.12–1.74)
 AECC definition 5 6634 0.66 (0.48–0.89) 0.001 77.9%
 The 2004 consensus definition of TRALI 1 218 0.91 (0.49–1.69)
Size of the population
 Small 5 2223 0.65 (0.44–0.98) 0.004 73.5%
 Large 2 5004 0.68 (0.52–0.88) 0.819 0.0%
Study design       
 Prospective cohort 2 2502 0.68 (0.52–0.88) 0.819 0.0%
 Retrospective cohort 3 1187 0.48 (0.35–0.66) 0.758 0.0%
 Case–control study 2 1036 0.90 (0.85–0.95) 0.972 0.0%
  1. ARDS acute respiratory distress syndrome, AECC American-European Consensus Conference, TRALI transfusion-related acute lung injury